

Preemptive policy: This is a P&T approved policy and can be used after the drug is FDA approved until it is superseded by an updated policy



## Clinical Policy: Narsoplimab (OMS721)

Reference Number: CP.PHAR.527

Effective Date: **FDA Approval Date**

Last Review Date: 05.25

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

Narsoplimab (OMS721<sup>®/TM</sup>) is an inhibitor of mannan-binding lectin-associated serine protease-2 (MASP-2).

### FDA Approved Indication(s) **[Pending]**

OMS721 is indicated for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) patients at high risk for poor outcomes.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that OMS721 is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria\*

*\*Criteria will mirror the clinical information from the prescribing information once FDA-approved*

##### A. Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (must meet all):

1. Diagnosis of HSCT-TMA;\*
2. Prescribed by or in consultation with a hematologist or transplant specialist;
3. Age  $\geq$  18 years;\*
4. Member has signs of persistent TMA as evidenced by presence of all of the following for at least 2 weeks after modification or discontinuation of calcineurin inhibitor therapy (e.g., cyclosporine, tacrolimus) (a, b, and c):\*
  - a. Platelet count  $\leq$   $150 \times 10^9/L$ ;
  - b. Hemolysis such as an elevation in serum lactate dehydrogenase (LDH);
  - c. Serum creatinine above the upper limits of normal or member requires dialysis;
5. Documentation that member does not have any of the following (a, b, and c):\*
  - a. A disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13 (ADAMTS13) deficiency;
  - b. Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS);
  - c. Atypical hemolytic uremic syndrome (aHUS);
6. OMS721 is not prescribed concurrently with Soliris<sup>®</sup> or Ultomiris<sup>®</sup>;\*
7. Dose does not exceed 4 mg/kg once weekly.\*

**Approval duration: 8 weeks**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
  - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
  - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy\***

*\*Criteria will mirror the clinical information from the prescribing information once FDA-approved*

**A. Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy**

(must meet all):

1. Member meets one of the following (a or b):
  - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
  - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy as evidenced by, including but not limited to, improvement in any of the following parameters (a, b, c, or d):\*
  - a. Improved measures of intravascular hemolysis (e.g., normalization of LDH);
  - b. Increased or stabilized platelet counts;
  - c. Improved or stabilized serum creatinine or estimated glomerular filtration rate (eGFR);
  - d. Reduced need for dialysis;
3. Member has not received OMS721 for > 12 weeks;
4. OMS721 is not prescribed concurrently with Soliris or Ultomiris;\*
5. If request is for a dose increase, new dose does not exceed 4 mg/kg once weekly.\*

**Approval duration: Up to 12 weeks total**

**B. Other diagnoses/indications (must meet 1 or 2):**

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):

- a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
- b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

### III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

### IV. Appendices/General Information

#### *Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

HSCT: hematopoietic stem cell transplant

TMA: thrombotic microangiopathy

#### *Appendix B: Therapeutic Alternatives*

Not applicable

#### *Appendix C: Contraindications/Boxed Warnings [Pending]*

- Contraindication(s): pending
- Boxed warning(s): pending

### V. Dosage and Administration [Pending]

Indication	Dosing Regimen	Maximum Dose
HSCT-TMA*	4 mg/kg IV once weekly*	4 mg/kg/week*

### VI. Product Availability [Pending]

Pending

### VII. References

1. Safety and efficacy study of OMS721 in patients with thrombotic microangiopathies. ClinicalTrials.gov. Available at: <https://clinicaltrials.gov/ct2/show/NCT02222545>. Accessed March 10, 2025.

2. Omeros. Omeros reports final efficacy and safety data from the narsoplimab pivotal trial in HSCT-TMA. Press release available at: <https://investor.omeross.com/news-releases/news-release-details/omeross-reports-final-efficacy-and-safety-data-narsoplimab>. Accessed January 11, 2024.
3. Rambaldi A, Smith M, Whitaker S, and Khaled K. Narsoplimab (OMS721) for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy. Slide presentation for Omeros webcast on October 22, 2020. Accessed January 26, 2021.

### Coding Implications **[Pending]**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPSC Codes	Description
Pending	Pending

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created pre-emptively	04.13.21	05.21
2Q 2022 annual review: no significant changes as drug is not yet FDA-approved; references reviewed and updated.	02.13.22	05.22
Template changes applied to other diagnoses/indications and continued therapy section.	10.04.22	
2Q 2023 annual review: no significant changes as drug is not yet FDA-approved; references reviewed and updated.	02.14.23	05.23
2Q 2024 annual review: no significant changes as the drug is not yet FDA-approved; references reviewed and updated.	01.11.24	05.24
2Q 2025 annual review: no significant changes as the drug is not yet FDA-approved; references reviewed and updated.	01.29.25	05.25

### Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2021 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.